Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
Acta Pharmacol Sin
; 43(6): 1473-1483, 2022 Jun.
Article
in En
| MEDLINE
| ID: mdl-34654875
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Non-alcoholic Fatty Liver Disease
Limits:
Animals
Language:
En
Journal:
Acta Pharmacol Sin
Journal subject:
FARMACOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
China